ReviewCurrent opinion in endocrinology, diabetes, and obesity2019
Enforcing the checkpoints: harnessing T-cell exhaustion for therapy of T1D.
Review in Current opinion in endocrinology, diabetes, and obesity, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 29 citations in OpenAlex.
- Long-Term GAD-alum Treatment Effect on Different T-Cell Subpopulations in Healthy Children Positive for Multiple Beta Cell Autoantibodies.Journal of immunology research · 2022Trial
- TGF-β-mediated crosstalk between TIGITNature communications · 2024Article
- Breakdown and Repair of Peripheral Immune Tolerance in Type 1 Diabetes.Cold Spring Harbor perspectives in medicine · 2024Review
- Interconnected lineage trajectories link conventional and natural killer (NK)-like exhausted CD8Communications biology · 2024Article
- Mechanism of Action of OralVaccines · 2024Article
- Autoimmune CD8+ T cells in type 1 diabetes: from single-cell RNA sequencing to T-cell receptor redirection.Frontiers in endocrinology · 2024Review
- T-cell exhaustion-related genes in Graves' disease: a comprehensive genome mapping analysis.Frontiers in endocrinology · 2024Article
- Teplizumab.Hospital pharmacy · 2023Review
- Immune-related adverse events after immune check point inhibitors: Understanding the intersection with autoimmunity.Immunological reviews · 2023Review
- Teplizumab: type 1 diabetes mellitus preventable?European journal of clinical pharmacology · 2023Review
- A Concerted Vision to Advance the Knowledge of Diabetes Mellitus Related to Immune Checkpoint Inhibitors.International journal of molecular sciences · 2023Review
- Hypoxia drives CD39-dependent suppressor function in exhausted T cells to limit antitumor immunity.Nature immunology · 2023Article
- Guidelines for standardizing T-cell cytometry assays to link biomarkers, mechanisms, and disease outcomes in type 1 diabetes.European journal of immunology · 2022Article
- T-cell exhaustion in immune-mediated inflammatory diseases: New implications for immunotherapy.Frontiers in immunology · 2022Review
- CD8 + T Cells Exhibit an Exhausted Phenotype in Hemophagocytic Lymphohistiocytosis.Journal of clinical immunology · 2021Article
- Soluble Antigen Arrays Efficiently Deliver Peptides and Arrest Spontaneous Autoimmune Diabetes.Diabetes · 2021Article
- The many faces of islet antigen-specific CD8 T cells: clues to clinical outcome in type 1 diabetes.Immunology and cell biology · 2021Review
- Review
- Glycolysis Inhibition Induces Functional and Metabolic Exhaustion of CD4Frontiers in immunology · 2021Article
- Autoreactive CD8+ T cell exhaustion distinguishes subjects with slow type 1 diabetes progression.The Journal of clinical investigation · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewAlthough checkpoint inhibitor blockade is now widely used clinically for cancer immunotherapy, the reverse process, (i.e. induction of checkpoints to slow autoimmunity) has not been extensively explored. CD8 T-cell exhaustion is a state of immune hyporesponsiveness that may be harnessed to treat autoimmunity. RECENT
findingsWe focus on the potential role of CD8 T-cell exhaustion as a mechanism of peripheral tolerance in T1D and its therapeutic implications. SUMMARY: CD8 T-cell exhaustion is a continuum in which cells change from precursor to terminally exhausted cells. Current thinking based on studies in cancer and chronic viral infection invokes a three-signal model for development of T-cell exhaustion, with persistent antigen, negative costimulatory signals and chronic inflammation comprising signals 1-3, respectively. Transcriptional signatures of CD8 T-cell exhaustion were associated with better prognosis across several autoimmune diseases, most profoundly in systemic diseases. In T1D, CD8 exhaustion was promoted by treatment with anti-CD3 therapy (teplizumab) and was more evident in islet-specific CD8 T cells of slow progressors, suggesting a beneficial role in T1D also. Thus, we apply this three-step process of exhaustion to discuss potential treatments to augment CD8 T-cell exhaustion in T1D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.